Staci Sabnis
15Patents
5h-index
30Co-inventors
58Inventor score
Filing activity: Mar 14, 2014 → Jul 21, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10207010B2 | Compositions and methods for delivery of agents | Chemistry; Metallurgy | 86 | Active |
| US9925277B2 | Polynucleotide compositions containing amino acids | Human Necessities | 20 | Active |
| US10258698B2 | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | Chemistry; Metallurgy | 10 | Active |
| US11001861B2 | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 | Chemistry; Metallurgy | 10 | Active |
| US11969506B2 | Lipid nanoparticle formulation | Chemistry; Metallurgy | 6 | Active |
| US10494636B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | Human Necessities | 3 | Active |
| US10993918B2 | Polynucleotides encoding citrin for the treatment of Citrullinemia type 2 | Human Necessities | 2 | Active |
| US10519455B2 | Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease | Human Necessities | 1 | Active |
| US10485885B2 | Compositions and methods for delivery of agents | Chemistry; Metallurgy | 1 | Active |
| US11285222B2 | Compositions and methods for delivery of agents | Chemistry; Metallurgy | 1 | Active |
| US11649461B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | Human Necessities | 1 | Active |
| US10556018B2 | Compositions and methods for delivery of agents | Chemistry; Metallurgy | 1 | Active |
| US12377136B2 | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria | Chemistry; Metallurgy | 0 | Active |
| US12252704B2 | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 | Chemistry; Metallurgy | 0 | Active |
| US12239742B2 | Polynucleotides encoding Citrin for the treatment of Citrullinemia type 2 | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.